• Intravesical p21 mRNA-LNP: Tumor Suppressor Therapy in Bladd

  2026-06-20

  This study presents a non-viral, intravesical administration of p21 mRNA–loaded lipid nanoparticles as a tumor suppressor replacement strategy for bladder cancer. The work demonstrates significant tumor growth suppression and restoration of p21 expression using localized mRNA delivery, providing strong evidence for the clinical potential of RNA-based therapeutics in non-muscle-invasive bladder cancer.

• Gramine Triggers Ferroptosis via CUL3–MTDH in TNBC Models

  2026-06-19

  This study identifies Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a potent inducer of ferroptosis in triple-negative breast cancer (TNBC) by targeting the CUL3–MTDH ubiquitination axis. The findings introduce a novel mechanism for TNBC suppression and provide a mechanistic foundation for leveraging Gramine in cancer biology research.

• 3X (DYKDDDDK) Peptide: Optimizing FLAG Tag Workflows in Rese

  2026-06-19

  The 3X (DYKDDDDK) Peptide unlocks higher sensitivity and specificity in protein purification and detection, outperforming conventional FLAG tags in structural and functional assays. Its unique calcium-dependent properties and minimized interference empower advanced workflows from affinity purification to crystallography.

• PRDX6-GPX4 Axis: Enhancing Ferroptosis-Mediated Tumor Suppre

  2026-06-18

  Hu et al. (2025) uncover a dual mechanism by which PRDX6 regulates GPX4 localization and lipid peroxidation repair, conferring resistance to ferroptosis in cancer cells. Inhibiting PRDX6 sensitizes tumors to ferroptosis, revealing a promising therapeutic target for overcoming tumor resistance.

• M344: Precision HDAC Inhibition for Neuroblastoma and Beyond

  2026-06-18

  Explore how the histone deacetylase inhibitor M344 enables precision modulation of gene expression in neuroblastoma and cancer research. This in-depth article reveals unique mechanistic insights, protocol guidance, and the latest evidence, distinguishing itself from existing content.

• Palmitic acid (Hexadecanoic Acid): Technical Use in Research

  2026-06-17

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a high-purity, well-characterized saturated long-chain fatty acid for in vitro research on lipid metabolism, protein palmitoylation, and metabolic disorder pathways. It should not be used in protocols requiring aqueous solubility or long-term solution stability.

• Canagliflozin as an SGLT2 Inhibitor: Workflows and Innovatio

  2026-06-17

  Canagliflozin empowers researchers to move beyond glucose lowering, enabling precise modulation of renal glucose reabsorption and mitochondrial dynamics in metabolic disease models. This guide translates the latest mitochondrial remodeling findings into actionable protocols and troubleshooting tips, maximizing the experimental value of this selective SGLT2 inhibitor from APExBIO.

• LDH Cytotoxicity Assay Kit: Precision in Cell Damage Quantif

  2026-06-16

  The LDH Cytotoxicity Assay Kit empowers researchers to accurately assess cell cytotoxicity and apoptosis without the hazards of radioactivity, streamlining workflows from nanomaterial biocompatibility to disease modeling. Leveraging insights from advanced nanocomposite studies, this kit offers robust, reproducible quantification for cutting-edge biomedical applications.

• NMDA (N-Methyl-D-aspartic acid): Applied Workflows in Excito

  2026-06-16

  NMDA (N-Methyl-D-aspartic acid) unlocks precise modeling of excitotoxicity and oxidative stress in neurodegenerative disease research. Discover stepwise experimental strategies, evidence-driven protocol parameters, and practical troubleshooting tips for maximizing assay reproducibility with APExBIO’s high-purity NMDA.

• Betaine Hydrochloride in Metabolic Enzyme Research Workflows

  2026-06-15

  Betaine hydrochloride drives reproducibility and sensitivity in metabolic enzyme and protease assays, thanks to its high solubility and rigorous purity. This guide bridges recent anti-inflammatory cancer research with best-practice protocols to maximize assay success, offering workflow tips and troubleshooting insights unavailable in standard product datasheets.

• Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance

  2026-06-15

  Saracatinib (AZD0530) empowers researchers to dissect Src/Abl-driven oncogenic and synaptic pathways with nanomolar precision. Its robust efficacy in cell proliferation, migration, and in vivo tumor models, combined with well-defined troubleshooting protocols, makes it the gold standard for translational cancer and neurobiology research.

• Berberrubine Chloride: Multi-Target Insights for Translation

  2026-06-14

  Berberrubine chloride (9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride) is rapidly emerging as a versatile, mechanistically rich research tool for cancer, metabolic, and inflammatory disease investigations. This thought-leadership article synthesizes the latest mechanistic evidence, translational workflow guidance, competitive landscape analysis, and strategic foresight for researchers seeking to harness Berberrubine chloride’s unique multi-pathway actions in preclinical and clinical models. Drawing from peer-reviewed studies, recent workflow guides, and APExBIO’s product intelligence, we offer actionable recommendations and a roadmap for maximizing the translational impact of this multi-target alkaloid.

• Pentoxifylline Modulates Hyperinflammation in Preterm Monocy

  2026-06-13

  This study systematically investigates the immunomodulatory effects of pentoxifylline on LPS-stimulated monocytes from preterm infants, revealing significant downregulation of pro-inflammatory markers and cytokines. The findings provide mechanistic insights into age-dependent immune modulation relevant to neonatal sepsis and inform future translational research in targeted immunosuppression.

• TFEB Drives PD-L1 Mediated mTOR Inhibitor Resistance in RCC

  2026-06-12

  This study reveals that transcription factor EB (TFEB) upregulates PD-L1 and underlies immune evasion and resistance to mTOR inhibitors in renal cell carcinoma (RCC). By elucidating the TFEB–PD-L1 axis, the research provides a mechanistic rationale for combined mTOR and PD-L1 targeting in RCC therapy.

• Paclitaxel (Taxol) in Cancer Research: Protocols & Solutions

  2026-06-12

  Paclitaxel (Taxol) stands apart for its robust, reproducible microtubule stabilization and proven performance in cancer cell cycle studies. This guide delivers actionable workflows, troubleshooting insights, and translational tips for maximizing its use in both cell-based and in vivo research.

461 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page